Evidence map›Paper›PMID 36092389›Full record

ArticleInterdisciplinary perspectives on infectious diseases2022

Behavioural Risk for HIV, Hepatitis B, and Hepatitis C Infections among a Population of Drug Users and Injectors across Four Regions in Ghana.

Chris Guure, Sharren Margaret Obiri-Yeboah Laryea, Samuel Dery, Carlota Baptista da Silva, Comfort Asamoah-Adu, Stephen Ayisi-Addo, Maria-Goretti Loglo, Adamu Mohammed, Kwasi Torpey

Open access · goldAbstract read
In one paragraph

Article in Interdisciplinary perspectives on infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Chris GuureDepartment of Biostatistics, School of Public Health, University of Ghana, Legon, Accra, Ghana.ORCID https://orcid.org/0000-0001-6595-9587
Sharren Margaret Obiri-Yeboah LaryeaDepartment of Biostatistics, School of Public Health, University of Ghana, Legon, Accra, Ghana.
Samuel DeryDepartment of Biostatistics, School of Public Health, University of Ghana, Legon, Accra, Ghana.
Carlota Baptista da SilvaInternational Consultant, Harm Reduction and Key Population Expert, Lisbon, Portugal.
Comfort Asamoah-AduWest Africa Program to Combat AIDS, Accra, Ghana.
Stephen Ayisi-AddoNational AIDS/STI Control Programme, Ghana Health Service, Accra, Ghana.
Maria-Goretti LogloInternational Drug Policy Consortium, East Legon, Accra, Ghana.
Adamu MohammedWest Africa Behavioural Health Addictions and Recovery Management, Accra, Ghana.
Kwasi TorpeyDepartment of Population Family and Reproductive Health School of Public Health, University of Ghana, Legon, Accra, Ghana.
University of Ghana · GHGhana Health Service · GH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Blood borne infections such as HIV, Hepatitis B (HBV), and Hepatitis C (HCV) are of great importance to governments and their implementing partners, especially among people who use drugs (PWUD) and people who inject drugs (PWID). Prevalence and determinants of HIV, HBV, and HCV among PWUD and PWID in Ghana are not well established, the significance of this study. Method: This assessment was a cross-sectional study implemented via the respondent driven sampling approach. A team of community advisory boards that comprised former users, current users, and civil society organizations were constituted to help in the implementation of the study. The study was conducted in four regions in Ghana. The assessment was based on a representation of populations of PWID and PWUD from the four regions. Efforts were made by the team to ensure adequate representation of women where feasible. A quantitative questionnaire was developed and used to obtain information on the respondents' sociodemographics, sexual behavior, substance use, and biological characteristics. The prevalence of HIV, HBV, and HCV among PWID and PWUD was determined using blood samples. First response and oral quick test for confirmation of HIV positivity were carried out, while SD bioline was used to test for the presence of HBV and HBC. Data were analyzed using the Bayesian generalized linear model via the binomial family of distributions under the logit link function with weak Cauchy and Normal distribution as prior. Results: A total of 323 PWUD and PWID participants were interviewed across four regions of Ghana. The overall median age of the respondents was 36 (28, 43) years. The prevalence of HIV, HBV, and HCV infection in the study was 2.5%, 4.6%, and 5.9%, respectively. The prevalence of HIV, HBV, and HCV among drug users was 2.5% (95% CI: 0.7%-4.2%), 4.1% (95% CI: 1.8%-6.2%), and 6.7% (95% CI: 3.9%-9.4%), respectively. Most drug injectors and users started using and injecting drugs at ages less than 20 years and between 20 and 29 years, respectively. Drug users who identified themselves as part of the general population were 66% less likely to be tested HIV positive (POR = 0.34, CrI: 0.12-0.81) compared to sex workers. Part time employment respondents had fivefold odds (POR = 5.50, CrI: 1.20-16.16) of being HBV positive as against full-time employment. Conclusion: Most of the injectors and users started drugs at an early age. Drug users and injectors are at higher risk of these infections because of associated risky sexual behaviors and risky injection practices. Harm reduction programs to help addicts who are willing to quit the practice are recommended.

Identifiers

PMID36092389
PMCPMC9458387
OpenAlexW4294068972

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.